ClinicalTrials.gg

Program

Carbamazepine

Also written as “carbamazepine”, “Mirdametinib and Carbamazepine” and “Radiprodil with Carbamazepine”.

Its studies are mostly in Epilepsy · Bipolar Disorder · Tuberous Sclerosis · Neuralgia · Hepatitis C, led by 4 companies.

Furthest: phase 4, since Apr 11, 20256 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GRIN Therapeutics21 open or runningphase 1since Apr 11, 2025Apr 11, 2025none ahead
H. Lundbeck20 open or runningphase 3since May 21, 2010Mar 1, 2010none ahead
Novartis10 open or runningphase 4since Mar 17, 2010Mar 17, 2010none ahead
Validus Pharmaceuticals10 open or runningphase 4since Nov 24, 2015Nov 24, 2015none ahead

Also a collaborator on its studies: parexel, avance-clinical-pty-ltd, arvinas-estrogen-receptor-inc, Ligand Pharmaceuticals, icon-clinical-research and quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 1, 2010First study: phase 1 study in EpilepsyNew to H. LundbeckH. Lundbeck · NCT01079351 · 98 enrolled
  2. Mar 17, 2010Novartis's first study: phase 4 study in NeuralgiaNew to NovartisNovartis · NCT01089855 · 123 enrolled · Morocco
  3. May 21, 2010Phase 3 study in EpilepsyH. Lundbeck · NCT01128959 · 108 enrolled · United States
  4. Nov 24, 2015Validus Pharmaceuticals's first study: phase 4 study in Bipolar DisorderNew to Validus PharmaceuticalsValidus Pharmaceuticals · NCT02623504 · 17 enrolled · United States
  5. Apr 11, 2025GRIN Therapeutics's first study: phase 1 study in Tuberous SclerosisNew to GRIN TherapeuticsGRIN Therapeutics · NCT06965881 · 30 enrolled · Australia
  6. Oct 8, 2026Phase 1 study in Healthy Adult ParticipantsGRIN Therapeutics · NCT07884734 · 36 enrolled · United States

TargetBeta

“Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07884734Healthy Adult Participants · United States1Active, not recruitingGRIN TherapeuticsOct 31, 202636
NCT06965881Tuberous Sclerosis · Australia1TerminatedGRIN TherapeuticsJul 8, 202530
NCT02623504Bipolar Disorder · United States4TerminatedValidus PharmaceuticalsNov 1, 201817
NCT01128959Epilepsy · United States3CompletedH. LundbeckJan 2013108
NCT01089855Neuralgia · Morocco4CompletedNovartisJul 2010123
NCT01079351Epilepsy1CompletedH. LundbeckMar 200998

How it is read

Names in the registry

  • “Carbamazepine”, 13 entries
  • “carbamazepine”, 2 entries
  • “Mirdametinib and Carbamazepine”, 1 entry
  • “Radiprodil with Carbamazepine”, 1 entry
  • “Intravenous Carbamazepine (IV CBZ)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.